Titlebook: Handbook of Antimicrobial Resistance; Matthias Gotte,Albert Berghuis,Donald Sheppard Living reference work 20200th edition

我要沮喪

燒瓶

Antiviral Drug Resistance in Herpesviruses,) and varicella-zoster virus (VZV) infections. The modest activity of ACV against human cytomegalovirus (HCMV) has prompted the development of another nucleoside analogue, ganciclovir (GCV), for the management of systemic and organ-specific HCMV diseases. Second-line agents such as the pyrophosphate

GEM

Azole Resistance in ,: Mechanisms, Route of Resistance Selection, and Clinical Implications,rophytic mold .. However, acquired azole resistance in . is an emerging problem that compromises the clinical efficacy of azole antifungals. Several mutations in the cyp51A gene of . affect the activity of all mold-active antifungal azoles. These mutations result in the complete loss of activity of

取之不竭

要素

Drug Resistance in ,,o vaccine available yet, the control of these parasites relies solely on chemotherapy. Low-cost antimony-derived compounds remain the primary antileishmanial treatment in most developing countries. Increasing drug resistance towards these molecules has forced the use of alternative therapies in high

毗鄰

NUDGE

HBV Therapy and the Problem of Drug Resistance,e risk of liver disease progression, including cirrhosis, hepatic failure, and hepatocellular carcinoma. Nucleos(t)ide analogue monotherapy is commonly used as first-line therapy, and most patients will require long-term antiviral therapy. As for all direct-acting antiviral agents, the emergence of

含鐵

HIV Drug Resistance in Mothers and Infants Following Use of Antiretrovirals to Prevent Mother-to-Chection in the plasma is standard of care for prevention of mother-to-child transmission of HIV (.). In many resource-limited communities, financial and infrastructure limitations preclude ART for pregnancy. Instead, abbreviated PMTCT regimens of short-term antiretrovirals (.) (mono- or dual therapy)

IOTA

HIV Protease Inhibitor Resistance,fic HIV protease inhibitors (PIs), based on thorough understanding of the structure of HIV protease and its substrate, serves as a prime example of structure-based drug design. The introduction of first-generation PIs marked the start of combination antiretroviral therapy. However, low bioavailabili

cushion

HIV-1 Drug Resistance in Preexposure Prophylaxis Trials,tive in multiple randomized, placebo-controlled clinical trials throughout the world. Preexposure prophylaxis trials have included over 20,000 men and women at risk for HIV infection through sexual or intravenous exposure. A consistent finding is that drug exposure is essential for PrEP efficacy. In